Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 543 results for "Victoza"

Human medicines European public assessment report (EPAR): Vi...

This is a summary of the European public assessment report (EPAR) for Victoza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 2 weeks ago

30 images for Victoza

FiercePharma, 3 weeks ago
diaTribe, 4 weeks ago
Nasdaq, 4 weeks ago
diaTribe, 4 weeks ago
AfricanSeer, 1 month ago
DataMonitor HealthCare, 1 month ago
Nasdaq, 1 month ago, 1 month ago
Nasdaq, 1 month ago, 1 month ago

Is $2.8 Billion Just The Beginning For This Novo Nordisk Diabetes Drug

Image source: . With annualized sales approaching $2.8 billion, Novo Nordisk's (NYSE: NVO) Victoza is already a top-selling diabetes drug, but Victoza sales could be about to head even higher. Earlier this month,management released data showing ...
 Nasdaq4 weeks ago What Is It About Novo Nordisk's Diabetes Drug That Makes It a Top Seller?  Motley Fool1 month ago Novo diabetes drug cuts heart risks...  LocalNews7.com1 month ago Novo Slumps as Study on Victoza's Heart Impact Disappoints  Bloomberg1 month ago

Novo Nordisk: Victoza's Cardiovascular Victory

Novo Nordisk (NYSE: NVO ) just released a very positive cardiovascular outcomes trial result for their type-2 diabetes medication Victoza (liraglutide) but the market responded with a 5% drop in Novo's share price. Why? I believe the answer is a ...
 Seeking Alpha1 month ago Novo Slumps As Leader Looks More Like A Follower  Seeking Alpha1 month ago Novo Nordisk (NVO) Reports Positive Trial Results on Victoza  Nasdaq1 month ago Diabetes Drug LixiLan Shows Positive Results for Phase 3 Trials  MedIndia1 month ago

Good News for Type 2 Diabetics

Liraglutide (Victoza) may reduce cardiovascular risk in type 2 diabetics, according to a new study. In a double-blind trial, 9,340 patients were randomized to liraglutide or matching placebo and followed for an average of 3.8 years. The primary ...
 AHC Media3 weeks ago Victoza┬« provides significantly greater blood sugar reduction than lixisenatide in new clinical trial  Hospital Pharmacy Europe1 month ago treatment with liraglutide reduces the risk of heart attack and stroke in patients with type 2 diabetes  HCPLive1 month ago ADA 2016: Data from LEADER will allow Victoza to compete directly with Jardiance in type 2 diabetes patients with high CV risk  DataMonitor HealthCare1 month ago

Lilly's dulaglutide matches Victoza in study, but the real loser is AstraZeneca's Bydureon

Novo Nordisk's Victoza--FiercePharma file photo Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line ...
 FiercePharma2 weeks ago Will GLP market growth save Novo's Victoza from Lilly's new Trulicity?  FiercePharma3 weeks ago Lilly fortifies its Trulicity case with new Lantus add-on data  FiercePharma1 month ago

Victoza Reduces Cardiovascular Death by 22% in Type 2 Diabetes

LEADER results announced at #2016ADA compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease and 31% reduction in severe hypoglycemia. More results from this groundbreaking trial. Breaking ...
 diaTribe1 month ago GLP-1 Victoza Reduces Cardiovascular Death by 22% in Type 2 Diabetes  diaTribe4 weeks ago Breaking News from ADA: Victoza Reduces Cardiovascular Death by 22% in Type 2 Diabetes  diaTribe1 month ago

Are Expensive Diabetes Drugs Worth It?

Thursday, June 23rd, 2016 15:24 (MedPage Today) -- Jardiance and Victoza improve hard outcomes, but at a hefty cost related news Cath Lab Recap: Hearts From Space; Renal Denervation Again; Mobile Cardiac Care Thursday, June 23rd, 2016 15:24 ...
 NewsFlow241 month ago

Novo Nordisk's diabetes drugVictozacuts cardiovascular risk by 13 percent: study

Novo Nordisk reporteddetailed results from the LEADER trial showingthat its diabetes therapy Victoza (liraglutide) reduced the risk ofmajorcardiovascular (CV)events and death by a significant 13 percent,versus placebo, in adults with type 2 diabetes ...
 FirstWord Pharma1 month ago
Forbes Middle East

This Diabetes Drug Saves Lives. You Can Thank The FDA

This evening, researchers are announcing that the diabetes drug Victoza prevents heart attacks, strokes and cardiovascular deaths. It is only the second diabetes drug ever to do so. And doctors and Novo Nordisk give credit to the new diabetes data ...
 Global Advisors1 month ago

Novo Nordisk to Present New Data on Victoza, Tresiba, Insulin Aspart and Semaglutide at ADA

You currently are not registered for any FirstWord Pharma services. Register to FirstWord Pharma for free access to 10 articles every 30 days: You can also: Wait 27 days for your content allowance to be renewed. Sign up for a free trial to ...
 FirstWord Pharma1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
Get updated on latest news & your favorite topics right in your inbox!
More     Less